Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This will be a single centre, Phase 1, Placebo-controlled, Randomized, Doubleblind, SAD & MAD
Study to Assess the Safety, Tolerability and PK of HM201 in Healthy Subjects.